---
schema_version: "secwatch.filing_event.v1"
accession: "0001635088-26-000088"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2026-08-06T11:13:50+00:00"
generated_at: "2026-08-06T11:15:09.335579+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Roivant Q1 net loss $290.6M; cash $3.9B; brepocitinib launch on track for Sept 2026

## Summary
- Net loss of $290.6M ($0.26 per share) vs $273.9M ($0.33) in prior-year quarter; revenue $1.4M.
- Cash, equivalents, and marketable securities of $3.9B as of June 30, 2026; repurchased 7.3M shares for $208.7M in Q1.
- Brepocitinib on track for DM launch by end of September 2026; Phase 3 CS (BEACON+) enrolled first patients; NIU data H2 2026.
- Genevant received $950M from Moderna in July under $2.25B settlement; additional $1.3B contingent on §1498 appeal; new lawsuits against Pfizer/BioNTech in 21 jurisdictions.
- R&D expenses rose to $202M (+$49.1M) and G&A to $165.5M (+$31.5M), partly due to Moderna settlement bonuses.

## SEC filing metadata
- accession: 0001635088-26-000088
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2026-08-06T11:13:50+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/0001635088-26-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/roiv-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001635088-26-000088
- JSON: https://secwatch.observer/filing/0001635088-26-000088.json
- Plain text: https://secwatch.observer/filing/0001635088-26-000088.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.